Reni Benjamin
Stock Analyst at JMP Securities
(2.44)
# 1,434
Out of 4,496 analysts
116
Total ratings
46.83%
Success rate
-1.53%
Average return
Main Sectors:
Top Industries:
28 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HOWL Werewolf Therapeutics | Reiterates: Market Outperform | $12 | $2.72 | +341.18% | 4 | Jun 26, 2024 | |
| IOVA Iovance Biotherapeutics | Maintains: Market Outperform | $25 → $23 | $7.96 | +188.94% | 9 | Jun 20, 2024 | |
| KURA Kura Oncology | Reiterates: Market Outperform | $32 | $20.95 | +52.74% | 6 | Jun 18, 2024 | |
| BPMC Blueprint Medicines | Reiterates: Market Outperform | $125 | $114.97 | +8.72% | 11 | Jun 7, 2024 | |
| BCAB BioAtla | Maintains: Market Outperform | $12 → $5 | $1.70 | +194.12% | 7 | May 23, 2024 | |
| STRO Sutro Biopharma | Reiterates: Market Outperform | $17 | $3.77 | +351.53% | 7 | Apr 3, 2024 | |
| PRLD Prelude Therapeutics | Initiates: Market Outperform | $7 | $5.16 | +35.66% | 1 | Mar 13, 2024 | |
| SANA Sana Biotechnology | Maintains: Market Outperform | $8 → $15 | $5.80 | +158.62% | 3 | Mar 1, 2024 | |
| INCY Incyte | Downgrades: Market Perform | n/a | $65.87 | - | 14 | Feb 14, 2024 | |
| INBX Inhibrx | Downgrades: Market Perform | n/a | $12.88 | - | 6 | Jan 23, 2024 | |
| ALLO Allogene Therapeutics | Downgrades: Market Perform | n/a | $2.83 | - | 6 | Jan 5, 2024 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $44 → $32 | $22.33 | +43.30% | 10 | Dec 20, 2023 | |
| LVTX LAVA Therapeutics | Reiterates: Market Outperform | $6 | $2.06 | +191.26% | 4 | Aug 23, 2023 | |
| ACET Adicet Bio | Downgrades: Market Perform | n/a | $1.24 | - | 3 | Jun 27, 2023 | |
| CUE Cue Biopharma | Reiterates: Outperform | $15 | $0.76 | +1,870.31% | 2 | May 15, 2023 | |
| EFTR eFFECTOR Therapeutics | Maintains: Market Outperform | $50 → $25 | $0.06 | +45,354.55% | 5 | Jan 9, 2023 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.82 | +119.78% | 1 | Aug 8, 2022 | |
| MGNX MacroGenics | Upgrades: Market Perform | n/a | $4.92 | - | 2 | Feb 7, 2019 | |
| RGNX REGENXBIO | Upgrades: Strong Buy | n/a | $12.58 | - | 2 | Feb 5, 2019 | |
| LPTX Leap Therapeutics | Maintains: Outperform | n/a | $2.07 | - | 2 | Dec 19, 2018 | |
| VYGR Voyager Therapeutics | Upgrades: Strong Buy | n/a | $8.37 | - | 2 | Nov 15, 2018 | |
| ADVM Adverum Biotechnologies | Downgrades: Market Perform | n/a | $8.17 | - | 2 | Nov 2, 2018 | |
| ADAP Adaptimmune Therapeutics | Maintains: Outperform | n/a | $1.17 | - | 1 | Oct 22, 2018 | |
| ADMA ADMA Biologics | Maintains: Outperform | n/a | $13.36 | - | 2 | Oct 12, 2018 | |
| TGTX TG Therapeutics | Downgrades: Outperform | n/a | $21.00 | - | 1 | Sep 25, 2018 | |
| URGN UroGen Pharma | Downgrades: Market Perform | n/a | $15.79 | - | 1 | Nov 15, 2017 | |
| ONVO Organovo Holdings | Downgrades: Market Perform | n/a | $0.59 | - | 1 | Nov 10, 2017 | |
| BOLD Boundless Bio | Initiates: Market Perform | n/a | $3.56 | - | 1 | Oct 12, 2017 |
Werewolf Therapeutics
Jun 26, 2024
Reiterates: Market Outperform
Price Target: $12
Current: $2.72
Upside: +341.18%
Iovance Biotherapeutics
Jun 20, 2024
Maintains: Market Outperform
Price Target: $25 → $23
Current: $7.96
Upside: +188.94%
Kura Oncology
Jun 18, 2024
Reiterates: Market Outperform
Price Target: $32
Current: $20.95
Upside: +52.74%
Blueprint Medicines
Jun 7, 2024
Reiterates: Market Outperform
Price Target: $125
Current: $114.97
Upside: +8.72%
BioAtla
May 23, 2024
Maintains: Market Outperform
Price Target: $12 → $5
Current: $1.70
Upside: +194.12%
Sutro Biopharma
Apr 3, 2024
Reiterates: Market Outperform
Price Target: $17
Current: $3.77
Upside: +351.53%
Prelude Therapeutics
Mar 13, 2024
Initiates: Market Outperform
Price Target: $7
Current: $5.16
Upside: +35.66%
Sana Biotechnology
Mar 1, 2024
Maintains: Market Outperform
Price Target: $8 → $15
Current: $5.80
Upside: +158.62%
Incyte
Feb 14, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $65.87
Upside: -
Inhibrx
Jan 23, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $12.88
Upside: -
Allogene Therapeutics
Jan 5, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.83
Upside: -
Bicycle Therapeutics
Dec 20, 2023
Maintains: Market Outperform
Price Target: $44 → $32
Current: $22.33
Upside: +43.30%
LAVA Therapeutics
Aug 23, 2023
Reiterates: Market Outperform
Price Target: $6
Current: $2.06
Upside: +191.26%
Adicet Bio
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.24
Upside: -
Cue Biopharma
May 15, 2023
Reiterates: Outperform
Price Target: $15
Current: $0.76
Upside: +1,870.31%
eFFECTOR Therapeutics
Jan 9, 2023
Maintains: Market Outperform
Price Target: $50 → $25
Current: $0.06
Upside: +45,354.55%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.82
Upside: +119.78%
MacroGenics
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $4.92
Upside: -
REGENXBIO
Feb 5, 2019
Upgrades: Strong Buy
Price Target: n/a
Current: $12.58
Upside: -
Leap Therapeutics
Dec 19, 2018
Maintains: Outperform
Price Target: n/a
Current: $2.07
Upside: -
Voyager Therapeutics
Nov 15, 2018
Upgrades: Strong Buy
Price Target: n/a
Current: $8.37
Upside: -
Adverum Biotechnologies
Nov 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $8.17
Upside: -
Adaptimmune Therapeutics
Oct 22, 2018
Maintains: Outperform
Price Target: n/a
Current: $1.17
Upside: -
ADMA Biologics
Oct 12, 2018
Maintains: Outperform
Price Target: n/a
Current: $13.36
Upside: -
TG Therapeutics
Sep 25, 2018
Downgrades: Outperform
Price Target: n/a
Current: $21.00
Upside: -
UroGen Pharma
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $15.79
Upside: -
Organovo Holdings
Nov 10, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $0.59
Upside: -
Boundless Bio
Oct 12, 2017
Initiates: Market Perform
Price Target: n/a
Current: $3.56
Upside: -